Seyed Mohammad Hossein Hosseini - Research Laboratory of Green Organic Synthesis & Polymers, Department of Chemistry, Iran University of Science and Technology
Mohammad Reza Naimi-Jamal - Research Laboratory of Green Organic Synthesis & Polymers, Department of Chemistry, Iran University of Science and Technology
Maryam Hassani - Research Laboratory of Green Organic Synthesis & Polymers, Department of Chemistry, Iran University of Science and Technology

Irritable bowel syndrome (IBS) is a disorder of intestinal function characterized by chronic pain in the abdominal region, discomfort, bloating, and changes in bowel habits with no other organic causes. Diarrhea and constipation are the dominant signs of this disease that may alternately appear. One of the most commonly used treatments for this disease is the use of antispasmodic drugs such as Mebeverine hydrochloride (MBH), which can directly affect the smooth muscle of the gastrointestinal tract and relieve spasms caused by that without affecting the intestinal motility. Accordingly, the mechanism of action for this specific drug has a direct relaxing effect on smooth muscle. Some studies have shown that the anti-contractile effect of Mebeverine is not only limited to a specific system, which can consequently result in multiple side effects. By using nanotechnology and nano-carriers, biodegradation of drugs or biologically active substances can be prevented, and target cells can also be reached. The rate of drug release is slow but nonstop. In this study, Mebeverine hydrochloride drug was encapsulated using niosomic carriers. Correspondingly, niosomes were prepared using thin-layer dipping techniques, including specific cholesterol ratios, tween ۸۰, and polyethylene glycol. After that, the size of the particle diameter and the amount of encapsulation and drug release were measured. Finally, it was indicated that the drug release from the formulation was at a slow rate.

Controlled release, Niosome, Mebeverine hydrochloride, Tween, polyethylene glycol